Parallel Advisors
ELVN icon

Parallel Advisors’s Enliven Therapeutics ELVN Stock Holding History

Parallel Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$779 Hold
17
– – ﹤0.01% 3822
2026
Q2 		$863 Buy
+17
New +$722 ﹤0.01% 3713
2025
Q4 		– Sell
-491
Closed -$10.1K – 3657
2025
Q3 		$10.1K Buy
491
+463
+1,654% +$9.33K ﹤0.01% 2528
2025
Q2 		$562 Buy
28
+18
+180% +$341 ﹤0.01% 3294
2025
Q1 		$197 Buy
10
+6
+150% +$129 ﹤0.01% 3382
2024
Q4 		$90 Buy
+4
New +$104 ﹤0.01% 3445

Other funds holding ELVN

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Parallel Advisors's ELVN Position: Q3 2026 in Review

Parallel Advisors held its Enliven Therapeutics (ELVN) position steady in Q3 2026 at 17 shares worth $779. The position accounts for ﹤0.01% of the portfolio, ranked #3822.

Parallel Advisors first reported a position in ELVN in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.1K in Q3 2025. 38 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Parallel Advisors held 17 shares of Enliven Therapeutics worth $779 as of Q3 2026.
  • Parallel Advisors left its Enliven Therapeutics share count unchanged in Q3 2026.
  • Enliven Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3822 holding.
  • Parallel Advisors first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Parallel Advisors's Enliven Therapeutics position peaked at $10.1K in Q3 2025.
  • 38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.